| Target Price | $943.50 |
| Price | $952.40 |
| Deviation | 0.93% |
| Number of Estimates | 32 |
| 32 Analysts have issued a price target Regeneron Pharmaceuticals 2027 . The average Regeneron Pharmaceuticals target price is $943.50. This is 0.93% lower than the current stock price. The highest price target is $1,233.75 29.54% , the lowest is $749.53 21.30% . | |
| A rating was issued by 36 analysts: 26 Analysts recommend Regeneron Pharmaceuticals to buy, 10 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2027 of 0.93% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
31 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
12 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2026. The average Regeneron Pharmaceuticals EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
32 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Regeneron Pharmaceuticals net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
32 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Regeneron Pharmaceuticals...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Nov 02 2026 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Nov 02 2026 |
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Nov 02 2026 |
| Bernstein |
Market Perform
➜
Market Perform
|
Unchanged | Nov 02 2026 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Nov 02 2026 |
| Baird |
Neutral
➜
Neutral
|
Unchanged | Nov 02 2026 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Nov 02 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Nov 02 2026 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Nov 02 2026 |
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Nov 02 2026 |
|
Unchanged
Bernstein:
Market Perform
➜
Market Perform
|
Nov 02 2026 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Nov 02 2026 |
|
Unchanged
Baird:
Neutral
➜
Neutral
|
Nov 02 2026 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Nov 02 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


